BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:MK-1406 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of MK-1406\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07300085-11242@assetmemo.bio
DTSTAMP:20261121T005600Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:MK-1406: Phase 1 readout est. (NCT07300085)
DESCRIPTION:MK-1406\, phase 1.\nStudy: A Trial to Evaluate the Effect of CD
 388/MK1406 on the Immunogenicity of Fluzone® HD Vaccine (CD388.SQ.1.08/MK
 -1406-007)\nEstimated primary completion: 31 December 2026. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/mk-1406#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07300085
URL:https://assetmemo.bio/drug/mk-1406#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07743151-11242@assetmemo.bio
DTSTAMP:20261121T005600Z
DTSTART;VALUE=DATE:20270205
DTEND;VALUE=DATE:20270206
SUMMARY:MK-1406: Phase 1 readout est. (NCT07743151)
DESCRIPTION:MK-1406\, phase 1.\nStudy: A Clinical Trial of MK-1406 in Healt
 hy Participants (MK-1406-008)\nEstimated primary completion: 5 February 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/mk-1406#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07743151
URL:https://assetmemo.bio/drug/mk-1406#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07159763-11242@assetmemo.bio
DTSTAMP:20261121T005600Z
DTSTART;VALUE=DATE:20270702
DTEND;VALUE=DATE:20270703
SUMMARY:MK-1406: Phase 3 readout est. (NCT07159763)
DESCRIPTION:MK-1406\, phase 3.\nStudy: A Study to Evaluate the Safety and E
 fficacy of MK-1406/CD388 for Prevention of Influenza (MK-1406-005/CD388.SQ
 .3.06)\nEstimated primary completion: 2 July 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/mk-1406#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07159763
URL:https://assetmemo.bio/drug/mk-1406#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07225959-11242@assetmemo.bio
DTSTAMP:20261121T005600Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:MK-1406: Phase 2 readout est. (NCT07225959)
DESCRIPTION:MK-1406\, phase 2.\nStudy: A Study of Annual Doses of MK-1406/C
 D388 in Healthy Adults (MK-1406-006/CD388.SQ.2.07)\nEstimated primary comp
 letion: 31 July 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /mk-1406#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07225959
URL:https://assetmemo.bio/drug/mk-1406#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
